ERBB2 and neoplasm: Given the established synergic effects of dalpiciclib with letrozole, anastrozole and fulvestrant in a phase Ib trial (NCT03481998, Hengrui data on file) and the purpose to further improve anti-tumor activities, dalpiciclib is currently under evaluation in combination with endocrine therapy for HR-positive and HER2-negative ABC in two phase 3 trials: one in combination with letrozole or anastrozole in the frontline setting (NCT03966898) and one in combination with fulvestrant in the later-line setting (NCT03927456).